Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mycobiome cape gooseberries

ABSTRACT: Mycobiome cape gooseberries Metagenome

PROVIDER: PRJNA1158320 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30621057_1.fastq.gz	Fastqsanger.gz
	SRR30621057_2.fastq.gz	Fastqsanger.gz
	SRR30621058_1.fastq.gz	Fastqsanger.gz
	SRR30621058_2.fastq.gz	Fastqsanger.gz
	SRR30621059_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 36

Similar Datasets

Rat Skin Mycobiome

Project description:Rat Skin Mycobiome Metagenome

| PRJNA476563 | ENA

Expression data from Nasopharyngeal carcinoma (NPC) cell lines treated or untreated with Caffeic acid phenethyl ester (CAPE)

Project description:CAPE has anti-bacterial and viral infection, anti-oxidant, anti-inflammatory, and anti-tumor properties.We found that CAPE suppressed the proliferation and colony-formation ability of NPC cells. We used microarrays to identify differential genes regulated by CAPE in NPC cells and futher analys the potential GO and pathway

2019-02-16 | GSE126608 | GEO

WT macrophage response to WT L. monocytogenes, with or without CAPE treatment

Project description:Transcriptional profiling of WT macrophages infected with WT L. monocytogenes for 180 minutes, with or without CAPE treatment Keywords: Drug comparison.

2008-01-01 | GSE8102 | GEO

Protection of SH-SY5Y cells against 6-OHDA by 3,4-dihydroxybenzalacetone (DBL) and caffeic acid phenethyl ester (CAPE)

Project description:3,4-dihydroxybenzalacetone (DBL) and Caffeic acid phenethyl ester (CAPE) are both catechol-containing phenylpropanoid derivatives. In the present study, we compared the neuroprotective characteristics of these compounds and other phenylpropanoid derivatives against Parkinson’s disease-related neurotoxin 6-hydroxydopamine (6-OHDA). Pretreatment of human SH-SY5Y neuroblastoma cells with DBL or CAPE, but not with other compounds, prevented 6-OHDA-induced cell death, with marked effects observed for CAPE. To identify the mechanism, we compared gene expression profiles induced by these compounds in SH-SY5Y cells.

2020-01-31 | GSE93639 | GEO

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190103 | GEO

Fungal mycobiome drives IL33 secretion and type 2 immunity in pancreatic cancer

Project description:We report the RNAseq of mouse pancreatic cancer cell lines with Kras ON vs Kras OFF. TH2 and innate lymphoid cells 2 (ILC2) can stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL4, IL5 and IL13. However, the mechanisms by which type 2 immune cells traffic to the tumor microenvironment (TME) are unknown. Here, in pancreatic ductal adenocarcinoma (PDAC), we show that oncogenic KrasG12D (Kras*) increases the expression of IL33 in cancer cells, which upon secretion recruits and activates the TH2 and ILC2. Correspondingly, cancer cell-specific deletion of IL33 reduces TH2 and ILC2 recruitment and promotes tumor regression. Unexpectedly, we discovered that the cellular release of IL33 into the TME is dependent on the intratumoral fungal mycobiome. Genetic deletion of IL33 or anti-fungal treatment decreases TH2 and ILC2 infiltration and increases survival. Consistent with these murine data, high IL33 expression is observed in approximately 20% of human PDAC, and expression is mainly restricted to cancer cells. These data expand our knowledge of the mechanisms driving PDAC tumor progression and identifies therapeutically targetable pathways involving intratumoral mycobiome-driven secretion of IL33.

2022-03-01 | GSE190468 | GEO

Proteomic insights into the molecular composition of Cape cobra (Naja nivea) venom

Project description:True cobras of the genus Naja are venomous snakes with particular medical importance in Africa and Asia. The Cape cobra Naja nivea is one of the most toxic of the African true cobras, but the composition of its venom has rarely been investigated using proteomics methods.

2024-10-08 | PXD036965 | Pride

WT macrophage response to WT L. monocytogenes, with or without CAPE treatment

Project description:Transcriptional profiling of WT macrophages infected with WT L. monocytogenes for 180 minutes, with or without CAPE treatment Keywords: Drug comparison. Experiment in WT background, with WT bacteria, with or without drug treatment. Multiple biological replicates (see array names), with one replicate per array.

2010-05-27 | E-GEOD-8102 | biostudies-arrayexpress

Human Gut Mycobiome

Project description:Human Gut Mycobiome

| PRJNA960810 | ENA

aquatic mycobiome

Project description:Aquatic mycobiome Raw sequence reads

| PRJNA764564 | ENA